Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) announced today that it has completed the process of collecting and reviewing its Phase I data, further to its January 16, 2015 press release. As a result, Antibe has resumed the development of ATB-346.

ATB-346's pharmacokinetic profile, coupled with data on cyclooxygenase inhibition in humans (an efficacy biomarker) suggests a target therapeutic dose at or below 250 mg daily, a much lower level than initially anticipated. It also provides a possible explanation for the safety issues observed at the 750 mg and 1500 mg doses. At a dose of 250 mg given once daily for 14 days, ATB-346 was safe and well tolerated in the Phase 1 study.

Accordingly, the Company has concluded its Phase I study and plans to conduct additional validating studies, prior to continuing with a full Phase 2 program. The company has made significant reductions in its overheads and will concentrate its resources on completing the above studies.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer analgesic for severe acute pain.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Important Note on Forward Looking Statements

Copyright Business Wire 2010